NYSEAMERICAN : OSTX
OS Therapies Incorporated — Financial statements
Healthcare · Biotechnology · United States
Last price 1.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 57.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cost of Revenue | 1.21K | 1.16M | ||||
| Gross Profit | -1.21K | -1.16M | ||||
| Selling, General & Admin | 11.63M | 12.34M | 3.97M | 1.13M | 1.15M | 1.50M |
| Research & Development | 25.98M | 16.36M | 2.84M | 3.22M | 3.29M | 2.17M |
| Operating Expenses | 37.61M | 28.71M | 6.81M | 4.34M | 4.45M | 3.68M |
| Operating Income | -37.61M | -28.71M | -6.81M | -4.34M | -4.45M | -4.84M |
| Interest Expense | -80.92K | -2.05M | -3.45M | -1.81M | -2.58M | |
| Interest & Investment Income | 210.00 | 249.00 | 2.00 | |||
| Other Non Operating Income (Expenses) | -1.68M | -48.39K | -17.25K | |||
| Pretax Income | -39.37M | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
| Net Income | -39.37M | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
| Preferred Dividends & Other Adjustments | 31.25K | 125.00K | 125.00K | 93.75K | ||
| Net Income to Common | -39.37M | -28.75M | -8.91M | -7.92M | -6.38M | -7.51M |
| Shares Outstanding (Basic) | 37.40M | 29.25M | 6.95M | 5.43M | 9.98M | 9.98M |
| Shares Outstanding (Diluted) | 37.40M | 29.25M | 6.95M | 5.43M | 9.98M | 9.98M |
| EPS (Basic) | -1.05 | -0.98 | -1.28 | -1.46 | -0.64 | -0.75 |
| EPS (Diluted) | -1.05 | -0.98 | -1.28 | -1.46 | -0.64 | -0.75 |
| Free Cash Flow | -18.53M | -14.24M | -7.28M | -3.01M | -3.79M | -4.41M |
| Free Cash Flow Per Share | -0.50 | -0.49 | -1.05 | -0.55 | -0.38 | -0.44 |
| EBITDA | -37.11M | -28.34M | -6.81M | -4.34M | -4.45M | -4.84M |
| D&A For EBITDA | 499.75K | 363.08K | 2.78K | 4.22K | 805.00 | 805.00 |
| EBIT | -37.61M | -28.71M | -6.81M | -4.34M | -4.45M | -4.84M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 205.03K | 269.83K | 5.53M | 38.98K | 171.48K | 80.79K |
| Cash & Short-Term Investments | 205.03K | 269.83K | 5.53M | 38.98K | 171.48K | 80.79K |
| Receivables | 3.10M | 1.15K | 231.07K | |||
| Prepaid Expenses | 337.71K | 63.08K | ||||
| Other Current Assets | 751.05K | 324.21K | 956.00 | |||
| Total Current Assets | 3.64M | 332.91K | 5.53M | 790.03K | 496.83K | 312.81K |
| Property, Plant & Equipment | 1.10K | 2.49K | 5.27K | 8.05K | 12.27K | 13.08K |
| Other Intangible Assets | 6.26M | 6.50M | ||||
| Total Assets | 9.90M | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Accounts Payable | 20.25M | 9.94M | 1.66M | 2.72M | 1.23M | 856.52K |
| Accrued Expenses | 18.36K | 1.45M | 618.27K | 2.33M | 1.66M | 933.95K |
| Short-Term Debt | 2.48M | |||||
| Current Portion of Long-Term Debt | 12.13M | |||||
| Other Current Liabilities | 375.00K | 375.00K | 2.35M | 5.05M | 3.26M | 1.71M |
| Total Current Liabilities | 20.64M | 11.76M | 4.63M | 24.71M | 6.15M | 3.50M |
| Long-Term Debt | 10.35M | 7.07M | ||||
| Long-Term Unearned Revenue | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Other Long-Term Liabilities | 1.47M | 1.11M | ||||
| Total Liabilities | 20.74M | 11.86M | 4.73M | 24.81M | 18.07M | 11.78M |
| Common Stock | 45.28K | 37.12K | 20.87K | 5.34K | 9.98K | 9.98K |
| Additional Paid-In Capital | 74.26M | 61.05M | 35.14M | 5.50M | 4.03M | 3.76M |
| Retained Earnings | -86.22M | -67.19M | -38.43M | -29.52M | -21.60M | -15.22M |
| Total Common Equity | -11.91M | -6.10M | -3.27M | -24.02M | -17.56M | -11.45M |
| Shareholders' Equity | -10.84M | -5.02M | 811.49K | -24.02M | -17.56M | -11.45M |
| Total Liabilities & Equity | 9.90M | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Total Debt | 14.61M | 10.35M | 7.07M | |||
| Net Cash (Debt) | 205.03K | 269.83K | 5.53M | -14.57M | -10.18M | -6.99M |
| Net Cash Per Share | 0.01 | 0.01 | 0.80 | -2.68 | -1.02 | -0.70 |
| Filing Date Shares Outstanding | 46.13M | 39.53M | 21.66M | 11.98M | 10.72M | 10.72M |
| Total Common Shares Outstanding | 45.28M | 37.11M | 20.87M | 10.68M | 9.98M | 9.98M |
| Working Capital | -17.00M | -11.43M | 906.22K | -23.92M | -5.65M | -3.18M |
| Book Value Per Share | -0.26 | -0.16 | -0.16 | -2.25 | -1.76 | -1.15 |
| Tangible Book Value | -18.17M | -12.60M | -3.27M | -24.02M | -17.56M | -11.45M |
| Tangible Book Value Per Share | -0.40 | -0.34 | -0.16 | -2.25 | -1.76 | -1.15 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -39.37M | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
| Depreciation & Amortization | 499.75K | 363.08K | 2.78K | 4.22K | 805.00 | 805.00 |
| Other Amortization | 1.11M | 1.04M | 1.43M | 2.65M | 1.15M | 2.07M |
| Stock-Based Compensation | 5.76M | 4.86M | 293.30K | |||
| Other Operating Activities | -856.37K | 8.52K | 116.69K | 362.50K | 372.48K | |
| Change in Accounts Payable | 16.27M | 8.27M | -1.05M | 1.35M | 216.43K | 856.48K |
| Change in Other Net Operating Assets | -2.80M | 834.81K | 923.69K | 669.65K | 730.90K | -281.81K |
| Operating Cash Flow | -18.53M | -14.24M | -7.28M | -3.01M | -3.79M | -4.40M |
| Capital Expenditures | -11.93K | |||||
| Sale (Purchase) of Intangibles | -466.42K | |||||
| Other Investing Activities | 1.15K | 230.88K | 212.41K | |||
| Investing Cash Flow | -466.42K | 1.15K | 230.88K | 200.47K | ||
| Short-Term Debt Issued | 250.00K | |||||
| Long-Term Debt Issued | 1.50M | 3.16M | 3.82M | 2.95M | ||
| Total Debt Issued | 1.83M | 1.75M | 3.16M | 3.82M | 2.95M | |
| Short-Term Debt Repaid | -250.00K | |||||
| Total Debt Repaid | -250.00K | |||||
| Net Debt Issued (Repaid) | 1.83M | 1.50M | 3.16M | 3.82M | 2.95M | |
| Issuance of Common Stock | 13.57M | 7.86M | 5.23M | |||
| Other Financing Activities | 530.16K | 530.16K | -284.18K | -172.02K | 100.00K | |
| Financing Cash Flow | 15.94M | 9.44M | 12.78M | 2.87M | 3.65M | 3.05M |
| Net Cash Flow | -2.60M | -5.26M | 5.49M | -132.50K | 90.69K | -1.15M |
| Free Cash Flow | -18.53M | -14.24M | -7.28M | -3.01M | -3.79M | -4.41M |
| Free Cash Flow Per Share | -0.50 | -0.49 | -1.05 | -0.55 | -0.38 | -0.44 |
| Levered Free Cash Flow | -1.69M | -5.07M | -8.54M | 1.31M | -198.71K | -974.89K |
| Unlevered Free Cash Flow | -1.71M | -5.07M | -8.69M | 820.54K | -219.94K | -1.43M |
| Cash Interest Paid | 10.00K | |||||
| Change in Working Capital | 13.47M | 9.11M | -129.64K | 2.02M | 947.33K | 574.67K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 57.29M | 49.30M | 90.90M | |||
| Enterprise Value | 57.09M | 48.49M | 89.04M | |||
| Last Close Price | 1.24 | 1.40 | 4.28 | |||
| Forward PE | 7.77 | |||||
| PB Ratio | -9.81 | 112.02 | ||||
| Debt / Equity Ratio | -0.61 | -0.59 | -0.62 | |||
| Net Debt / Equity Ratio | 0.02 | 0.05 | -6.82 | -0.61 | -0.58 | -0.61 |
| Net Debt / EBITDA Ratio | 0.01 | 0.01 | 0.81 | -3.36 | -2.29 | -1.45 |
| Net Debt / FCF Ratio | 0.01 | 0.02 | 0.76 | -4.85 | -2.68 | -1.58 |
| Quick Ratio | 0.16 | 0.02 | 1.20 | 0.00 | 0.03 | 0.02 |
| Current Ratio | 0.18 | 0.03 | 1.20 | 0.03 | 0.08 | 0.09 |
| Return on Assets (ROA) | -232.65% | -289.88% | -134.41% | -415.27% | -665.62% | -301.75% |
| Return on Capital Employed (ROCE) | 350.10% | 582.90% | -747.60% | 18.20% | 78.90% | 152.60% |
| Earnings Yield | -84.89% | -58.32% | -9.77% | |||
| FCF Yield | -32.35% | -28.88% | -8.01% | |||
| Buyback Yield / Dilution | -125.88% | -320.90% | -28.01% | 45.60% | -18.50% |